Pharmaceutical regulatory data, drug approvals & compliance tracking
Access detailed information about obesity drug pipeline. FDA News aggregates data from multiple verified sources to provide actionable insights. Market conditions change rapidly, and staying informed is crucial for making sound decisions. This page aggregates the most relevant data points and presents them in an easily digestible format.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Regional variations can significantly impact the numbers shown. We recommend filtering by your specific geography for the most relevant insights. Our coverage spans major markets worldwide.
Updated regularly with the latest available data. Bookmark this page for easy access to current information. Sign up for our newsletter to receive updates directly.
| Drug | Company | Phase | Mechanism | Expected Filing |
|---|---|---|---|---|
| Orforglipron | PharmaCo A | Phase 3 | Oral GLP-1 | Q2 2027 |
| Survodutide | PharmaCo B | Phase 3 | Dual agonist | Q4 2026 |
| AMG-133 | BioTech C | Phase 2 | GIP/GLP-1 | Q1 2028 |
| Pemvidutide | PharmaCo D | Phase 2 | Dual agonist | Q3 2027 |
| Maridebart | BioTech E | Phase 3 | Activin II | Q1 2027 |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
